Macrophage depletion and vesicular stomatitis virus for treatment of cancer
AssigneeBoehringer Ingelheim International GmbH
InventorsMelissa MAYR, Monika PETERSSON
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of cancers and in particular to the treatment of cancers with a macrophage depleting agent and a recombinant vesicular stomatitis virus.
Claims7
A method of treating cancer in a subject comprising administering an antagonistic antibody which is directed against CSF1 or CSFR to the subject and further comprising administering a recombinant vesicular stomatitis virus to the subject and thereby treating the cancer, wherein in said vesicular stomatitis virus the gene coding for the glycoprotein G of the vesicular stomatitis virus is replaced by the gene coding for the glycoprotein GP of lymphocyte choriomeningitis virus (LCMV), and/or the glycoprotein G is replaced by the glycoprotein GP of LCMV.
The method according to any one of the preceding claims, wherein the recombinant vesicular stomatitis virus is administered concomittantly, sequentially or alternately with the antagonistic antibody.
A composition comprising an antagonistic antibody which is directed against CSF1 or CSFR and a recombinant vesicular stomatitis virus, wherein in said vesicular stomatitis virus the gene coding for the glycoprotein G of the vesicular stomatitis virus is replaced by the gene coding for the glycoprotein GP of lymphocyte choriomeningitis virus (LCMV), and/or the glycoprotein G is replaced by the glycoprotein GP of LCMV in said vesicular stomatitis virus.
A kit of parts comprising:
- a) A recombinant vesicular stomatitis virus or a pharmaceutical composition comprising said recombinant vesicular stomatitis virus, wherein in said vesicular stomatitis virus the gene coding for the glycoprotein G of the vesicular stomatitis virus is replaced by the gene coding for the glycoprotein GP of lymphocyte choriomeningitis virus (LCMV), and/or the glycoprotein G is replaced by the glycoprotein GP of LCMV in said vesicular stomatitis virus, and
- b) an antagonistic antibody which is directed against CSF1 or CSFR.
Dependencies are inferred from the claim text.